Paul L. Friedlander, M.D.
Clinical Associate Professor of Otolaryngology
Tulane Cancer Center Associate Member
Address: 1430 Tulane Ave., Box SL-59, New Orleans, LA 70112-2699
Dr. Friedlander received his B.S. in biology from Georgetown University and his M.D. from LSU (New Orleans). Following medical school, he completed a two-year general surgery residency at George Washington University, an otolaryngology residency at LSU (New Orleans), and a head and neck surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. In 1997, he joined the faculty at LSU, where the majority of his effort was in translational research in head and neck cancers. He established the head and neck tumor bank there, which was responsible for collecting clinical information and samples on 250 patients with head and neck cancers. He also participated in translaitonal research involving the use of modified adenoviruses in targeting head and neck cancer as well as immunomodulation of head and neck cancer using the CD40 ligand protein. He is currently investigating the possible role of the Hepatitis C virus as a cofactor in the development of head and neck cancer.
Nobles J, Hagan J, Wold C, Fazekas-May M, Gilbert J, Friedlander PL. Outcome analysis of patients with squamous cell carcinoma of the head and neck and hepatitis C. Laryngoscope, 115(10):1882-86, 2005.
Nobles J, Wold C, Fazekas-May MA, Friedlander PL. The incidence and epidemiology of hepatitis C virus (HCV) in patients with squamous cell carcinoma of the head and neck (SCCHN). Laryngoscope, 114 (112): 2119-22, 2004.
Lanson NA, Friedlander PL, Schwarzenberger P, Kolls JK, Wang G. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promotor causing tumor-selective tumorlysis. Cancer Research, 63(22): 7936-41, 2003.
Friedlander PL, Delaune CL, Abadie J, Toups M, LaCour J, Marrero L, Zhong Q, Kolls J. Immunoprotective effect of CD40 ligand gene therapy in malignant mesothelioma and squamous cell carcinoma. American Journal of Respiratory Cell and Molecular Biology, 29(3): 321-330, 2003.
Lalonde ES, Beyers G, Friedlander PL, Kolls J. Efficacy of transfection rates on head and neck squamous cell cancer by a novel adenovirus: an in vitro and in vivo study. Head and Neck, 24(12): 1038-1046, 2002.